Department of Cardiovascular Pharmacology, Amity Institute of Pharmacy, Amity University, Gurugram, Haryana 122413, India.
Department of Cardiovascular Pharmacology, Amity Institute of Pharmacy, Amity University, Gurugram, Haryana 122413, India.
Drug Discov Today. 2023 May;28(5):103558. doi: 10.1016/j.drudis.2023.103558. Epub 2023 Mar 21.
A healthy life depends on the inseparable relationship between a host and the gut microbiota. A healthy gut microbiota regulates intestinal integrity, whereas an unbalanced gut microbiota contributes to junctional remodeling and leads to dysbiosis. Bacterial infiltration and dysbiosis are reported to activate a series of pathological cascades that trigger metabolic abnormalities, including diabesity. Conversely, recent studies revealed that the incidence of dysbiosis itself is fuelled by diabesity. In this review, we highlight the molecular aspects of multifaceted pathological signaling between dysbiosis and diabetes that could pave the way for new drug discovery. Moreover, to reinstate the gut microbiota and restrict the epidemic of dysbiosis and diabesity, we also scrutinize a promising therapeutic strategy that can challenge the pathological interlink.
健康的生活取决于宿主与肠道微生物群之间不可分割的关系。健康的肠道微生物群调节肠道完整性,而失衡的肠道微生物群则有助于连接重塑,并导致菌群失调。据报道,细菌渗透和菌群失调会激活一系列病理级联反应,导致代谢异常,包括糖尿病肥胖症。相反,最近的研究表明,菌群失调本身的发生率是由糖尿病肥胖症推动的。在这篇综述中,我们强调了菌群失调和糖尿病之间多方面病理信号传递的分子方面,这可能为新药发现铺平道路。此外,为了恢复肠道微生物群,限制菌群失调和糖尿病肥胖症的流行,我们还仔细研究了一种有前途的治疗策略,可以挑战病理联系。